晨会纪要 证券研究报告 2026 年 03 月 31 日 核心结论 分析师 【医药生物】英科医疗（300677.SZ）首次覆盖深度报告：手套行业供需改 善，龙头深筑成本和产能优势 英科医疗为全球一次性防护手套龙头，具备突出的成本、产能和资金优势， 在中国和全球产能和收入规模领先。我们看好一次性手套行业落后产能逐步 出清，供需格局持续优化趋势下，公司持续扩建丁腈手套产能，提升市占率 和盈利能力，业绩增长具备较强的确定性。我们预计公司 2025/2026/2027 年 EPS 分别为 1.96/2.76/3.43 元。首次覆盖，给予"买入"评级。 【传媒】心动公司（02400.HK）2025 年业绩点评：TapTap 平台建设持续 深化，关注《心动小镇》海外表现 预 计 公 司 26/27/28 年 营 业 收 入 分 别 为 66.76/73.50/80.91 亿元， YoY+16%/10%/10%，归母净利润分别为 18.99/22.54/24.87 亿元，同比 +24%/19%/10%，TapTap 平台建设持续深化，关注《心动小镇》海外表现， 维持"买入"评级。 【建筑装饰】中国能建（601868.SH） ...

证 券 研 究 报 告 "制造强国"实干系列周报(26/03/29期) 证券分析师： ◼ 钠电：大部分乘用车电池能量密度低于145wh/kg，且北方地区新能源车渗透率低，低成本和宽温域的钠电在动力领域 替代空间巨大。钠电循环寿命长，宽温域也适合北方，钠电后续成本规模化降低下，其在储能全生命周期成本比锂电低。 钠电倍率性能强，适合启停、电动工具等高倍率场景 ◼ 装饰原纸：供需拐点确定，进军全球市场 ◼ 丁腈手套：上游原料供应趋紧，竞争格局优异，提价弹性巨大 ◼ 低空经济：亿航实现从技术认证到商业闭环，低空eVTOL载人运营开启在即 ◼ 风险提示：市场竞争加剧的风险；原材料价格波动风险；经济周期波动的风险 主要内容 3 1. 看好锂电和钠电Q2行情 2. 装饰原纸：供需拐点确定，进军全球市场 3. 丁腈手套：上游原料供应趋紧，竞争格局优异，提价弹性巨大 4. 亿航实现从技术认证到商业闭环，低空eVTOL载人运营开启在即 韩强 A0230518060003 屠亦婷 A0230512080003 王珂 A0230521120002 刘正 A0230518100001 马天一 A0230525040004 戴文杰 A0 ...

证券代码：300677 证券简称：英科医疗 公告编号：2026-014 英科医疗科技股份有限公司 关于子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"或"英科医疗"） 于 2025 年 4 月 23 日、2025 年 5 月 26 日分别召开的第四届董事会第 二次（定期）会议、第四届监事会第二次（定期）会议以及 2024 年 度股东大会，审议通过了《关于公司及子公司向银行申请授信额度及 担保事项的议案》。为满足公司及子公司的生产经营需要，公司及子 公司拟向银行等金融机构申请综合授信的额度以及金融衍生品交易 风险限额的总额（以下简称"授信额度"）不超过 360 亿元人民币， 对其担保总额不超过 360 亿元人民币，授权期限自公司 2024 年度股 东大会审议通过之日起至下一年度股东大会召开时止。具体内容详见 刊登于巨潮资讯网（www.cninfo.com.cn）的《关于公司及子公司向银 行申请授信额度及担保事项的公告》《2024 年度股东大会决议公告》 （公告编号：2025-046、2025-07 ...

Summary of Conference Call Notes Industry Overview - The report focuses on the pharmaceutical raw materials and nitrile gloves industries, highlighting pricing trends and supply chain dynamics [1][2]. Key Points on Pharmaceutical Raw Materials - The raw material supply side entered a capacity digestion phase in 2023, with no new marginal changes expected after 2025, leading to a slow price transmission trend in the industry [1]. - Downstream customer inventories are at historical lows, driven by a "buy high, sell low" mentality, which is expected to trigger a replenishment cycle, ensuring the sustainability of price increases [1][3]. - Significant price increases have been observed in antibiotics like 6-APA and petroleum-related products (calcium pantothenate, vitamin E), with price turning points for sartans expected in the second half of 2026 [1][5]. - The raw material pharmaceutical companies are expected to maintain stable gross margins due to the presence of low-cost inventory and the long supply chain, which mitigates the impact of upstream cost increases [3][4]. Investment Recommendations in Pharmaceutical Raw Materials - Companies with a high proportion of raw material pharmaceuticals, such as Prologis and Tianyu Co., are recommended for their potential profit elasticity during this price increase cycle [1][5]. Key Points on Nitrile Gloves Industry - The nitrile gloves industry is expected to see significant profit elasticity starting in Q2 2026, driven by rising raw material prices, particularly butadiene and nitrile latex [1][6]. - The supply is concentrating among leading companies as smaller manufacturers face cost pressures and may cease operations, while leading firms benefit from long-term supply agreements [7][8]. - The demand for nitrile gloves remains rigid, especially in the medical sector, which accounts for over 60% of usage, and distributors are likely to increase stockpiling in response to rising prices [7][8]. Price Trends and Supply Chain Dynamics in Nitrile Gloves - The price of nitrile latex, which constitutes about 63% of production costs, has surged from over 5,000 RMB per ton to over 9,000 RMB per ton since late February 2026, with butadiene prices also experiencing a significant increase [8]. - The price transmission from raw materials to finished nitrile gloves is expected to exceed the increase in raw material prices, indicating a strong upward trend in final product pricing [8][10]. Global Market Dynamics for Nitrile Gloves - The global demand for disposable gloves is stabilizing after a period of rapid growth during the pandemic, with a projected steady growth rate in the coming years [9]. - Over 90% of global production capacity is concentrated in China and Malaysia, with leading domestic companies like YK Medical and Blue Sail Medical expected to increase their market share due to lower production costs compared to Malaysian competitors [9]. Future Trends and Strategic Moves - The export prices of nitrile gloves are at historical lows due to tariffs affecting the U.S. market, but an increase in raw material prices is expected to lead to significant price hikes in the near future [10][11]. - The establishment of overseas production bases in Southeast Asia is crucial for restoring and expanding market share in the U.S., with companies like YK Medical and Zhonghong Medical accelerating their investments in this region [11]. Key Indicators for Investors - Investors should monitor the following indicators: 1. Changes in upstream raw material prices, particularly nitrile latex and butadiene [12]. 2. Order price adjustments by leading companies in both domestic and U.S. markets [12]. 3. Inventory levels and stockpiling trends among distributors [12]. 4. Progress in domestic and foreign companies' expansion in Southeast Asia [12].

Summary of Conference Call on Disposable Glove Industry Industry Overview - The disposable glove industry is experiencing price increases driven by supply-side factors, including the exit of small manufacturers and rising energy/raw material costs, leading to an upward shift in profit margins. [1] - The industry is expected to reach a supply-demand balance by 2024, with some medium-sized manufacturers operating at low capacity and small manufacturers exiting the market, setting the stage for price increases. [2] Key Companies and Their Performance Yingke Medical - Yingke Medical is a leading global manufacturer of disposable gloves, with total production capacity expected to reach 72.1 billion pieces by the end of 2025. [3] - The company has a self-supply rate of 70%-80% for nitrile latex, which enhances its cost advantage. Profit per glove is projected to increase from 2 cents to 3-4 cents. [3] - The expected operating profit for Yingke Medical is around 15 billion yuan, with potential to exceed 20 billion yuan by 2027 due to capacity expansion and industry profit increases. [3] Zhonghong Medical and Blue Sail Medical - Both companies were operating at a loss in 2025 but turned profitable by April 2026, with profit per glove around 1 cent. [5] - Zhonghong Medical has a nitrile glove capacity of 17.1 billion pieces, while Blue Sail Medical has 25.1 billion pieces, with an additional 4 billion pieces that can be adjusted based on demand. [5] - Estimated annual profits for Zhonghong Medical are around 180 million yuan, while Blue Sail Medical's profits are expected to be close to 200 million yuan. [5] Pricing and Profit Elasticity - The price of gloves is expected to rise from $17 to $23-24 per thousand gloves, with a cost increase of approximately $2, indicating significant profit elasticity. [1][7] - The current market conditions suggest that the price increase will not significantly affect demand, as the primary applications for disposable gloves are in the medical field, which has stable demand. [10] Risks and Monitoring - The supply of low-cost raw materials is expected to last until mid-May 2026, after which the impact of high-cost raw material procurement on profits will need to be monitored. [1][8] - The market is also concerned about the potential for demand shrinkage due to price increases, but historical data suggests that demand remains stable even with significant price hikes. [10] Additional Insights - The cost advantages of companies using coal over those using natural gas are expected to widen, further enhancing profitability for companies like Yingke Medical. [2][3] - The potential for PVC gloves to replace nitrile gloves is limited due to performance differences, and no significant trends toward substitution have been observed. [10]

Investment Rating - The report maintains a "Recommended" rating for the pharmaceutical industry as of March 16, 2026 [1] Core Insights - The report emphasizes the importance of products with price leadership amid rising costs in the supply chain due to geopolitical tensions and policy changes affecting raw material prices [2] - The report highlights the significant price increases in pharmaceutical raw materials, particularly vitamins and amino acids, which have seen price increases of 40.54% and 84.66% respectively since the beginning of the year [2] - The report notes the approval of China's first invasive brain-machine interface, marking a significant milestone in the medical device sector [5] - The report indicates a strong trend in China's innovative pharmaceuticals going global, with a notable increase in licensing-out transactions [6] Summary by Sections 1. Supply Chain Dynamics - The report discusses the impact of rising prices in upstream chemical products on pharmaceutical raw materials, stressing that the ability to pass on these costs is crucial for maintaining profitability [2] - It mentions that 90% of monitored products have seen price increases, with the chemical product price index rising by 28.52% since the beginning of the year [2] 2. Market Trends in Disposable Gloves - The report details the price increases in disposable nitrile gloves and PVC gloves due to rising costs of raw materials like butadiene and acrylonitrile, which have increased by 84.43% and 47.30% respectively [3] - It notes that the domestic utilization rate for nitrile gloves has improved, and export prices have been rising since late 2025 [3] 3. Regulatory Environment - The report highlights the impact of dual-use item management on the pricing of key materials, creating significant price disparities between domestic and international markets [4] - It suggests that stricter controls on resources like rare earths could enhance the competitive advantage of domestic medical products [4] 4. Innovations in Medical Devices - The report discusses the approval of the brain-machine interface by the National Medical Products Administration, which is expected to open new market opportunities [5] - It outlines the potential for significant market growth in this area, given the high number of spinal cord injury patients in China [5] 5. International Expansion of Chinese Pharmaceuticals - The report notes that there have been 39 licensing-out transactions in the innovative drug sector, with upfront payments totaling approximately $2.953 billion [6] - It emphasizes that the trend of Chinese pharmaceuticals going global continues to strengthen, with a focus on small nucleic acid drugs and dual antibodies [7] 6. Stock Recommendations - The report recommends focusing on raw material suppliers with price leadership, such as Zhejiang Medicine and Chuan Ning Biological, and highlights companies like Inco Medical and Blue Sail Medical in the disposable glove sector [8] - It also suggests monitoring companies involved in the invasive brain-machine interface and small nucleic acid drugs, indicating potential for growth in these areas [8]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The geopolitical tensions in the Middle East have led to increased volatility in international energy markets, affecting the prices of upstream raw materials and consequently the prices of glove products [5][14] - The production cost of nitrile gloves has risen approximately 28.9% due to significant increases in the prices of key raw materials, specifically butadiene and acrylonitrile, which have risen by 84.43% and 45.33% respectively since the end of 2025 [20][19] - The expected price for nitrile gloves is projected to rise to 17.5 yuan per thousand pieces [5] Summary by Sections Geopolitical Impact on Disposable Gloves - The geopolitical situation has caused a surge in oil prices, which directly impacts the prices of key raw materials for glove production [14][15] - The cost increase in raw materials is expected to be passed down the supply chain, leading to higher prices for end products [20][19] Medical Device Investment Directions for 2026 - The medical device sector is anticipated to see a gradual recovery in profits, driven by policy adjustments and the implementation of new procurement strategies [34] - Key areas of focus include brain-computer interfaces, AI medical technologies, and surgical robots, which are expected to receive increased attention and investment [34] Recommendations for Investment - Focus on leading companies that are likely to experience a turnaround in 2026, benefiting from brand strength and channel advantages [7] - Emphasize companies with strong R&D capabilities and clinically differentiated products to capitalize on policy corrections in high-value consumables [7] - Consider firms with established overseas operations and successful business development models to leverage international growth opportunities [7] - Target companies that are positioned to benefit from domestic policy support and accelerated localization efforts [7] - Monitor innovative sectors such as brain-computer interfaces and AI medical technologies for potential high-growth opportunities [7] Market Performance Overview - The pharmaceutical and biological sector saw a decline of 0.22%, underperforming the CSI 300 index by 0.41 percentage points [44] - The medical consumables sector experienced the highest growth, while the medical equipment sector faced the largest decline [46]

Investment Rating - The industry investment rating is "Positive" (maintained) [1] Core Insights - The geopolitical tensions in the Middle East have led to increased volatility in international energy markets, affecting the prices of upstream raw materials and consequently the prices of glove products [5][14] - The production cost of nitrile gloves has risen approximately 28.9% due to significant increases in the prices of key raw materials, specifically butadiene and acrylonitrile, which have risen by 84.43% and 45.33% respectively since the end of 2025 [20][29] - The expected price for nitrile gloves is projected to rise to 17.5 yuan per thousand pieces [5] Summary by Sections Geopolitical Catalysts in the Disposable Glove Industry - The geopolitical situation has caused a surge in oil prices, which directly impacts the prices of essential raw materials for glove production [14][15] - The cost of butadiene and acrylonitrile has increased significantly, leading to higher production costs for nitrile gloves [18][19] 2026 Medical Device Investment Directions - The medical device sector is expected to see a gradual recovery in profits, driven by policy adjustments and increased focus on high-value consumables [34] - The emphasis on brain-computer interfaces, AI medical technology, and surgical robots is anticipated to catalyze growth in related sectors [34] Recommended Focus Areas - Focus on leading companies that are expected to reverse their challenges in 2026, confirming performance inflection points [35] - High-value consumables are expected to see a correction in pricing policies, presenting opportunities for companies with strong R&D capabilities [36] - The international expansion of medical devices is opening new growth avenues, with companies that have established overseas certifications and partnerships being particularly well-positioned [38] - Domestic policies are accelerating the pace of localization, benefiting companies that are core beneficiaries of these policies [40] - The convergence of new technologies is creating significant opportunities in innovative sectors, with a focus on companies that can quickly commercialize their technologies [41] - Companies that can successfully expand into new business areas are likely to uncover new growth trajectories [42] Pharmaceutical Layout and Recommended Targets - The report maintains a positive outlook on the innovative drug sector and its supply chain, including CROs and AI technologies [8] - Monthly recommendations include companies such as WuXi AppTec, CSPC Pharmaceutical, and InnoCare Pharma, while weekly recommendations feature companies like HengRui Medicine and Frontier Biotech [8]

Investment Rating - The report maintains a "Buy" rating for the disposable gloves industry, indicating a positive outlook for future returns [4][62]. Core Insights - The disposable gloves industry is expected to see price increases due to rising costs of key raw materials influenced by geopolitical tensions in the Middle East and fluctuations in international energy markets [2][20]. - Domestic leading companies in the disposable gloves sector are anticipated to benefit from price hikes, the release of overseas production capacity, and natural growth in end-user demand [2][21]. - The report emphasizes the importance of clinical value in the pharmaceutical sector, recommending investments in innovative drug and medical device companies [3][22]. Summary by Sections Market Review - The A-share pharmaceutical index fell by 2.99%, underperforming the CSI 300 index by 2.11 percentage points, ranking 14th among 31 sub-industries [1][15]. - The Hong Kong Hang Seng Medical Health Index decreased by 7.16%, lagging behind the Hang Seng Index by 5.04 percentage points [1][15]. Disposable Gloves Industry - The industry is poised for price increases due to rising costs of raw materials such as butadiene and acrylonitrile, which are linked to the oil and gas sector [2][20]. - Domestic companies are expected to capture a larger share of the global market through cost control, supply chain integration, and R&D advantages [2][21]. Investment Strategy - The report suggests focusing on innovative drug chains and high-value medical devices, recommending companies like Innovent Biologics, WuXi AppTec, and Mindray Medical [3][24]. - The report highlights the potential for domestic leaders in the disposable gloves market, such as YTY Group, to benefit from price increases and overseas capacity utilization [2][21]. Company Performance Forecast - Key companies in the pharmaceutical sector are projected to have positive earnings growth, with specific EPS forecasts for 2024-2026 [4]. - The report includes a detailed earnings forecast and valuation table for several companies, indicating a "Buy" rating for most [4].

证券代码：300677 证券简称：英科医疗 公告编号：2026-013 英科医疗科技股份有限公司 关于为子公司提供担保事项的进展公告 本公司及董事会全体成员保证公告内容真实、准确和完整，没有 虚假记载、误导性陈述或重大遗漏。 英科医疗科技股份有限公司（以下简称"公司"）于 2025 年 4 月 23 日、2025 年 5 月 26 日分别召开的第四届董事会第二次（定期） 会议、第四届监事会第二次（定期）会议以及 2024 年度股东大会， 审议通过了《关于公司及子公司向银行申请授信额度及担保事项的议 案》。为满足公司及子公司的生产经营需要，公司及子公司拟向银行 等金融机构申请综合授信的额度以及金融衍生品交易风险限额的总 额（以下简称"授信额度"）不超过 360 亿元人民币，对其担保总额 不超过 360 亿元人民币，授权期限自公司 2024 年度股东大会审议通 过之日起至下一年度股东大会召开时止。具体内容详见刊登于巨潮资 讯网（www.cninfo.com.cn）的《关于公司及子公司向银行申请授信额 度及担保事项的公告》《2024 年度股东大会决议公告》（公告编号： 2025-046、2025-072）。 一、担 ...